WCWeiwen Chen

Weiwen Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Weiwen Chen has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Utilization of zoledronic acid and denosumab in patients with multiple myeloma: Real‐world experience from 13 427 patients

    by Weiwen Chen, Farheen Chunara, Mackenzie Lemieux, Sarvari Yellapragada, Carolina Schinke, Anita D'SOuza, Ghulam Rehman Mohyuddin, Aniko Szabo, Meera Mohan

  • Open Access

    Development of the MultIcultural commuNities co‐DeSigned ostEoporosis Toolkit Programme for People From Culturally and Linguistically Diverse: A Co‐Design Study

    by Clarice Tang, Bernadette Brady, Balwinder Sidhu, Danielle Ní Chróinín, David Lim, Lisa Woodland, Weiwen Chen, Carlos El‐Haddad, Stephen R. Carter, Jacqueline Center

    Purpose: Using experience‐based co‐design (EBCD) methodology, we aimed to co‐design and pilot a culturally adapted osteoporosis programme with older people from culturally and linguistically diverse (CALD) communities in Australia. Methods: This three‐phased study was conducted in one of the most culturally diverse regions in Australia. Twelve end users from three selected language communities with lived experience of osteoporosis and eight subject matter experts were recruited for the first two phases. Phases 1 and 2 utilised interviews and workshops to explore challenges experienced during osteoporosis diagnosis and management and co‐designed the key elements for the MultIcultural commuNities co‐DeSigned ostEoporosis Toolkit (MINDSET) programme. This programme was piloted with the selected communities (Phase 3) and evaluated for acceptability (participants' satisfaction) and efficacy. The latter was measured by comparing the differences in pre/post Osteoporosis Knowledge Assessment Tool (OKAT) scores among end users. Results: Common challenges identified included (i) lack of access to reliable information, (ii) osteoporosis perceived as a normal part of ageing, and (iii) lack of resources to guide discussions with general practitioners. The programme was piloted with 132 participants ( n = 46 Cantonese‐speaking, n = 52 Mandarin‐speaking and n = 34 Vietnamese‐speaking). All participants were highly satisfied with the programme, with 90% of participants stating that they would likely/very likely recommend the programme to others. A significant improvement in pre‐post scores on the OKAT was also observed across all groups (mean difference = +2.03, 95% CI 1.42 to 2.63, p < 0.001). Conclusions: MINDSET is an acceptable community‐based education programme to improve short‐term osteoporosis‐specific knowledge for people from selected culturally diverse backgrounds.

  • Open Access

    The effect of prior osteoporosis treatment on bone mineral density response to romosozumab

    by Brenda Ta, Flora Cheuk Wah Ho, Dana Bliuc, Weiwen Chen, Angela Sheu


  • Open Access

    The effect of prior osteoporosis treatment on bone mineral density response to romosozumab

    by Brenda Ta, Flora Cheuk Wah Ho, Dana Bliuc, Weiwen Chen, Angela Sheu

    BackgroundRomosozumab is an osteoanabolic agent with dual anabolic and antiresorptive effects, with substantial benefits on bone mineral density (BMD) and fracture risk reduction. BMD gains are attenuated by prior antiresorptive treatment. This study aimed to compare real-world effects of romosozumab on BMD and bone turnover markers (BTM) according to prior antiresorptive treatment.MethodsWe conducted a retrospective audit of patients who completed 12 months of romosozumab treatment between April 2021 and October 2024 at a tertiary hospital and affiliated clinics. Patients were analysed according to treatment history: treatment-naïve, prior bisphosphonate, or prior denosumab. Primary outcome was percentage change in BMD at the lumbar spine (LS) over 12 months. Secondary outcomes were percentage changes in femoral neck (FN), total hip (TH) BMD and bone turnover markers (procollagen type 1 n-propeptide and c-telopeptide) over 12 months. Between-group differences were assessed using ANCOVA and linear mixed models. Subgroup analyses examined the effect of duration of prior treatment and timing of transition from denosumab on BMD.ResultsSeventy-two patients were included (mean age 72.4 ± 11.9 years; 83% female). 20 patients were treatment naïve, 32 transitioned from bisphosphonates and 20 transitioned from denosumab. Patients in the treatment naïve group were younger, had lower baseline BMD and fracture risk compared to the bisphosphonate or denosumab group. LS BMD gains were significantly greater in treatment-naïve patients compared to those with prior bisphosphonate or denosumab exposure (13.1% vs 8.5% vs 4.4%, p=0.04). There were no significant differences in percentage change for FN or TH BMD across groups. A longer duration of prior antiresorptive therapy and later romosozumab initiation following denosumab were associated with smaller BMD gains. C-terminal teloptide (CTx) levels decreased in both treatment naïve and prior bisphosphate groups but transiently increased in the prior denosumab group before stabilising by 6–12 months.ConclusionIn our real-world cohort, romosozumab effectively increased BMD, particularly in treatment-naïve patients. Duration of prior antiresorptive therapy and timing of transition from denosumab significantly influenced BMD gains. Prospective studies are needed to optimise transition strategies from antiresorptive agents.

  • Excess subsequent fracture and mortality risk after ankle fractures: a relative survival analysis of the 45 and Up Study

    by Weiwen Chen, Lyn M. March, Fiona M. Blyth, Dunia Alarkawi, Robert D. Blank, Dana Bliuc, Thach Tran, Jacqueline R. Center

    Summary Ankle fractures are one of the common fractures that account for hospitalization. Ankle fractures were often thought of inconsequential as limited data on their long-term consequences. After accounting for age, sex, and time, ankle fractures were associated with increased risk of subsequent fracture and mortality. Background Ankle fractures are common but it is uncertain whether they are indicative of poor bone health. There are limited data about subsequent fracture and mortality risk following ankle fractures. Objective To determine if there is increased subsequent fracture and mortality risk after ankle fractures. Methods A prospective population-based cohort of 143,070 women and 123,818 men in the 45 and Up Study (NSW, Australia) had baseline questionnaire responses that were linked to Emergency Department Data Collection (EDDC), the Admitted Patient Data Collection (APDC), and the NSW Registry of Births Deaths & Marriages death registrations from 2006 to 2017. Secure data access was provided through the Sax Institute’s Secure Unified Research Environment (SURE). Sex-specific excess risks of subsequent fracture and mortality following ankle fractures were quantified using relative survival analysis. Results During 1,490,651 person-years, women and men experienced 1379 and 579 ankle fractures and 78 deaths and 76 deaths, respectively. Ankle fractures were associated with a 5-year 5% (95% CI 3–8%) excess risk of subsequent fracture in both women and men, compared to subjects’ risk of an incident fracture in the study. There was a 5-year cumulative excess mortality of 10% (95% CI 6–13%) following ankle fractures in men but no excess mortality in women compared to the overall cohort. Participants with ankle fractures who died were older (P < 0.001), more likely to have had a second fracture (P < 0.001), have had a prior fracture (P < 0.001), and have more comorbidities (P < 0.001). Conclusion In the 45 and Up cohort, there was a modest but significant increased risk of fracture following ankle fracture seen in both women and men. In men, but not women, ankle fractures were associated with 10% excess mortality. Ankle fractures should be considered for secondary fracture prevention in those who are older and have more comorbidities.


  • Denosumab and Mortality in a Real-World Setting: A Comparative Study

    by Dunia Alarkawi, Thach Tran, Weiwen Chen, Lyn M March, Fiona M Blyth, Robert D Blank, Dana Bliuc, Jacqueline R Center

    Denosumab (Dmab) is increasingly prescribed worldwide. Unlike bisphosphonates (BPs), its effect on mortality has yet to be well explored. This study examined the association between Dmab and all-cause mortality compared with no treatment in subjects with a fracture and BPs in subjects without a fracture. The study population was from the Sax Institute's 45 and Up Study (n = 267,357), a prospective population-based cohort with questionnaire data linked to hospital admissions (Admitted Patients Data Collection [APDC] data were linked by the Centre for Health Record Linkage), medication records (Pharmaceutical Benefits Scheme [PBS] provided by Services Australia), and stored securely (secure data access was provided through the Sax Institute's Secure Unified Research Environment [SURE]). The new-user cohort design with propensity-score (PS) matching was implemented. In the fracture cohort, Dmab and oral BP users were matched 1:2 to no treatment (Dmab: 617 women, 154 men; oral BPs: 615 women, 266 men). In the no-fracture cohort, Dmab users were matched 1:1 with oral BPs and zoledronic acid (Zol) users (Dmab:oral BPs: 479 men, 1534 women; Dmab:Zol: 280 men, 625 women). Mortality risk was measured using sex-specific pairwise multivariable Cox models. In the fracture cohort, compared with no treatment, Dmab was associated with 48% lower mortality in women (hazard ratio [HR] = 0.52, 95% confidence interval [CI] 0.36–0.72) but not in men. Oral BPs were associated with 44% lower mortality in both sexes (women HR = 0.56, 95% CI 0.42–0.77; men HR = 0.56, 95% CI 0.40–0.78). In the no-fracture cohort, compared with BPs, Dmab was associated with 1.5- to 2.5-fold higher mortality than oral BPs (women HR = 1.49, 95% CI 1.13–1.98; men HR = 2.74; 95% CI 1.82–4.11) but similar mortality to Zol. Dmab in women and oral BPs were associated with lower post-fracture mortality than no treatment. However, Dmab users had generally higher mortality than oral BP users in those without fractures. © 2023 American Society for Bone and Mineral Research (ASBMR).


  • Open Access

    The association between multimorbidity and osteoporosis investigation and treatment in high-risk fracture patients in Australia: A prospective cohort study

    by Dana Bliuc, Thach Tran, Weiwen Chen, Dunia Alarkawi, Dima A Alajlouni, Fiona Blyth, Lyn March, Kristine E Ensrud, Robert D Blank, Jacqueline R Center

    Background: Multimorbidity is common among fracture patients. However, its association with osteoporosis investigation and treatment to prevent future fractures is unclear. This limited knowledge impedes optimal patient care. This study investigated the association between multimorbidity and osteoporosis investigation and treatment in persons at high risk following an osteoporotic fracture. Methods and findings: The Sax Institute’s 45 and Up Study is a prospective population-based cohort of 267,153 people in New South Wales, Australia, recruited between 2005 and 2009. This analysis followed up participants until 2017 for a median of 6 years (IQR: 4 to 8). Questionnaire data were linked to hospital admissions (Admitted Patients Data Collection (APDC)), emergency presentations (Emergency Department Data Collection (EDDC)), Pharmaceutical Benefits Scheme (PBS), and Medicare Benefits Schedule (MBS). Data were linked by the Centre for Health Record Linkage and stored in a secured computing environment. Fractures were identified from APDC and EDDC, Charlson Comorbidity Index (CCI) from APDC, Dual-energy X-ray absorptiometry (DXA) investigation from MBS, and osteoporosis treatment from PBS. Out of 25,280 persons with index fracture, 10,540 were classified as high-risk based on 10-year Garvan Fracture Risk (age, sex, weight, prior fracture and falls) threshold ≥20%. The association of CCI with likelihood of investigation and treatment initiation was determined by logistic regression adjusted for education, socioeconomic and lifestyle factors). The high-risk females and males averaged 77 ± 10 and 86 ± 5 years, respectively; >40% had a CCI ≥2. Only 17% of females and 7% of males received a DXA referral, and 22% of females and 14% males received osteoporosis medication following fracture. A higher CCI was associated with a lower probability of being investigated [adjusted OR, females: 0.73 (95% CI, 0.61 to 0.87) and 0.43 (95% CI, 0.30 to 0.62); males: 0.47 (95% CI, 0.33 to 0.68) and 0.52 (0.31 to 0.85) for CCI: 2 to 3, and ≥4 versus 0 to 1, respectively] and of receiving osteoporosis medication [adjusted OR, females: 0.85 (95% CI, 0.74 to 0.98) and 0.78 (95% CI, 0.61 to 0.99); males: 0.75 (95% CI, 0.59 to 0.94) and 0.37 (95% CI, 0.23 to 0.53) for CCI: 2 to 3, and ≥4 versus 0 to 1, respectively]. The cohort is relatively healthy; therefore, the impact of multimorbidity on osteoporosis management may have been underestimated. Conclusions: Multimorbidity contributed significantly to osteoporosis treatment gap. This suggests that fracture risk is either underestimated or underprioritized in the context of multimorbidity and highlights the need for extra vigilance and improved fracture care in this setting.


  • Open Access

    The Contribution of Multimorbidity to Under-Diagnosis and Under-Treatment of Osteoporosis in High-Risk Fracture Patients

    by Dana Bliuc, Thach T. Tran, Weiwen Chen, Dunia Alarkawi, Dima A. Alajlouni, Fiona Blyth, Lyn March, Kristine Ensrud, Robert D. Blank, Jacqueline R. Center

    Background: Multimorbidity is common among fracture patients. This study determined the impact of multimorbidity on osteoporosis investigation and treatment in persons at high risk following an osteoporotic fracture. Methods: 45 and Up is a prospective population-based cohort of 267,153 people in Australia. Questionnaire data were linked to hospital admissions (Admitted Patients Data Collection –APDC), emergency presentations (Emergency Department Data Collection – EDDC) , Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS),. Fractures were identified from APDC and EDDC; Charlson Comorbidity Index (CCI) from APDC; DXA investigation from MBS; osteoporosis treatment from PBS.10,540 out of 25,280 persons with index fracture were classified as high-risk based on 10-year Garvan fracture risk (age, sex, weight, prior fracture and falls) threshold ≥ 20%. Association of CCI with likelihood of investigation and treatment initiation was determined by logistic regression. Findings: The high-risk women and men averaged 77 ± 10 and 86 ± 5 years, respectively; > 40% had a CCI ≥ 2. Only, 17% of women and 7% of men received a DXA referral, and 22% of women and 14% men received osteoporosis medication following fracture. A higher CCI was associated with a lower probability of being investigated and of receiving osteoporosis medication. Interpretation: Multimorbidity contributed significantly to osteoporosis treatment gap. This suggests that fracture risk is either under-estimated or under-prioritized in the context of multimorbidity and highlights the need for extra vigilance and improved fracture care in this setting. Funding Information: This study was supported by the NHMRC, Mrs. Gibson and Ernst Heine Family Foundation. Declaration of Interests: D. Bliuc, T. Tran, L. March, F. Blyth, D. Alarkawi and D. Alajlouni have no conflict of interest to declare. W. Chen has given educational talks for Amgen. K.E. Ensrud has received grants from the National Institute of Health. R.D. Blank has been a consultant for Bristol Myers Squibb, served on an advisory board for Amgen, received authorship royalties from Wolters Kluwer, received an editorial stipend from Elsevier, received travel support from Amgen, and owns stock in Abbott Labs, Abbvie, Amgen, JangoBio, and Procter & Gamble. J.R. Center has been on a medical advisory board for Amgen and given educational talks for Amgen and Teva. Ethics Approval Statement: 45 and Up study was approved by UNSW Human Research Ethics Committee. Ethics approval for the current study was obtained from the NSW Population Health Services Research Ethics Committee. Participants completed baseline and 5-year follow-up questionnaires and consented to have their medical records linked to administrative health databases.

  • Open Access

    Multimorbidity Increases Risk of Osteoporosis Under-Diagnosis and Under-Treatment in Patients at High Fracture Risk: 45 and up a Prospective Population Based-Study

    by Dana Bliuc, Thach Tran, Dunia Alarkawi, Weiwen Chen, Robert D Blank, Kristine E Ensrud, Fiona Blith, Lyn March, Jacqueline Center

    Background: Management of osteoporosis following fracture is suboptimal. Multimorbidity adds to clinical management complexity in the elderly but its contribution to the osteoporosis treatment gap has never been investigated. Objectives: To determine the impact of multimorbidity on fracture risk and on osteoporosis investigation and treatment in patients at high fracture risk. Design and Setting: The 45 and Up Study is a prospective population-based cohort study in NSW, Australia with questionnaire data linked to hospital records by the Centre for Health Record Linkage (CHeReL) and the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Scheme (MBS) data provided by Department of Human Services. Fractures identified from hospital records, comorbidities from questionnaires, hospital and PBS records. Bone mineral density (BMD) investigation obtained from MBS and treatment for osteoporosis from PBS. Participants: 16191 women and 9089 men with incident low-trauma fracture (2000 - 2017) classified in a high and low-risk group based on 10-year fracture risk threshold of 20% from the Garvan Fracture Risk Calculator (age, gender, prior fracture and falls). Main Outcome Measurements: Association of Charlson comorbidity index (CCI) with fracture. Likelihood of BMD investigation and treatment initiation. Outcomes ascertained by logistic regression and re-fracture risk by Cox models. Results: Individuals at high fracture risk were significantly older [women (mean age ±SD) 77 ± 10 vs 57 ±4 for high- vs low risk and men 86±5 vs 65±8 for high vs low risk] and had a higher morbidity burden [women, CCI ≥ 2 40% vs 12% for high- vs low-risk and men 53% vs 26% for high vs low risk]. Being in the high-risk group as well as a higher CCI were independently associated with > 2-fold higher risk of re-fracture. However, in the high-risk group, only 28% (48% women and 17% men) had a BMD investigation and 31% (24% women and 14% men) received anti-osteoporosis medication post-fracture. A higher CCI was associated with a lower probability of both BMD investigation [CCI 2–3 vs 0–1, RR 0.73 (0.65–0.82) for women, and 0.50 (0.40–0.64) for men and CCI ≥4 vs 0–1, RR 0.50 (0.41- 0.62) for women and 0.36 (0.25–0.52) for men] and treatment initiation [CCI 2–3 vs 0–1, RR 0.88 (0.77–0.98) for women and 0.75 (0.60–0.95) for men and CCI ≥4 vs 0–1, RR 0.75 (0.59- 0.95) for women and 0.35 (0.23–0.53) for men]. Conclusion: Multimorbidity, despite being associated with the highest fracture risk, significantly lowers the likelihood of osteoporosis investigation and treatment. These findings suggest that fracture risk is either under-estimated or under-prioritized in the context of multimorbidity. Our findings highlight the need for improved delivery of fracture preventive care in this setting. More generally, they also point out the need for a better understanding of how problems are prioritized in complex clinical situations.


  • Comorbidities Only Account for a Small Proportion of Excess Mortality After Fracture: A Record Linkage Study of Individual Fracture Types

    by Weiwen Chen, Judy M Simpson, Lyn M March, Fiona M Blyth, Dana Bliuc, Thach Tran, Tuan V Nguyen, John A Eisman, Jacqueline R Center

    : Nonhip, nonvertebral (NHNV) fractures constitute the majority of osteoporotic fractures, but few studies have examined the association between these fractures, comorbidity, and mortality. Our objective was to examine the relationship between individual nonhip, nonvertebral fractures, comorbidities, and mortality. The prospective population-based cohort of 267,043 subjects (45 and Up Study, Australia) had baseline questionnaires linked to hospital administrative and all-cause mortality data from 2006 to 2013. Associations between fracture and mortality were examined using multivariate, time-dependent Cox models, adjusted for age, prior fracture, body mass index, smoking, and comorbidities (cardiovascular disease, diabetes, stroke, thrombosis, and cancer), and survival function curves. Population attributable fraction was calculated for each level of risk exposure. During 1,490,651 person-years, women and men experienced 7571 and 4571 fractures and 7064 deaths and 11,078 deaths, respectively. In addition to hip and vertebral fractures, pelvis, humerus, clavicle, rib, proximal tibia/fibula, elbow and distal forearm fractures in both sexes, and ankle fractures in men were associated with increased multivariable-adjusted mortality hazard ratios ranging from 1.3 to 3.4. Comorbidity independently added to mortality such that a woman with a humeral fracture and 1 comorbidity had a similarly reduced 5-year survival as that of a woman with a hip fracture and no comorbidities. Population mortality attributable to any fracture without comorbidity was 9.2% in women and 5.3% in men. All proximal nonhip, nonvertebral fractures in women and men were associated with increased mortality risk. Coexistent comorbidities independently further increased mortality. Population attributable risk for mortality for fractures was similar to cardiovascular disease and diabetes, highlighting their importance and potential benefit for early intervention and treatment. © 2018 American Society for Bone and Mineral Research.